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Aarau, SwitzerlandObjectives. Matrix-metalloproteinase (MMP)-2 and -9 and aminoterminal propeptide of type III collagen (NIIINP) have
been reported to be elevated in patients with abdominal aortic aneurysm (AAA). The aim of our study was to test NIIINP,
MMP-2 and -9 as potential serum markers for AAA in a large population group at risk for AAA.
Methods. Fifty-five to 70 year old men were screened for AAA by abdominal ultrasound. Simultaneously, blood samples
were taken and the patients were interviewed for known risk factors for AAA. Patients with a dilatation of the infrarenal
aorta ofR25 mm (Group 1, nZ76) were compared to randomly assigned patients with normal aortic diameters (Group 2,
nZ83). A third group consisted of patients scheduled for operation of AAA (nZ19).
Results. A total of 987 men were investigated with ultrasound. Seventy-six (7.7%) had an aortic dilatation R25 mm.
Aortic dilatation was correlated with age (PZ0.0001). However, serum levels of NIIINP and MMP 2 were not different
between the three groups of patients. For MMP-9 there was a weak inverse correlation with lower serum levels in patients
with aortic dilatation (PZ0.043).
Conclusions. Both MMP-2 and -9 and NIIINP failed to show relevance as serum markers for aortic dilatation. Our results
are, therefore, in contradiction to previous published results. AAAs cannot be diagnosed with a simple blood test.Keywords: Abdominal aortic aneurysm; Serum marker; Metalloproteinases.Introduction
Ruptured abdominal aortic aneurysm (AAA) is
associated with a high rate of fatality and is an
important cause of sudden death.1,2 Early detection
through screening has been the only available way of
detecting the majority of AAA in the community.3–9
Degradation of extracellular matrix proteins in the
aortic wall is a key event in the formation of AAA,
resulting in decreased elastin concentration and
increased collagen turnover. Several studies have
shown the presence and involvement of matrix
metalloproteinases (MMP) and aminoterminal pro-
peptide of type III procollagen (NIIINP) in AAA
disease. Theoretically, highly expressed soluble MMP
or NIIINP could be continuously released into the
systemic circulation and be measurable in the blood of
patients with AAA. Preliminary studies haveing author. Thomas Eugster, MD, Vascular Unit,
ospital, CH-4031 Basel, Switzerland.
: teugster@uhbs.ch
0378 + 05 $35.00/0 q 2005 Elsevier Ltd. All rights resersuggested this concept.10–15 The purpose of our
study was to determine the validity of MMP-2 and -9
and NIIINP as serum markers for AAA in a large
cohort at risk for AAA.Patients and Methods
We were invited to join a large prospective study
initiated by our colleagues from urology. The study
invites all male inhabitants at the age of 55–70 years
from our county (i.e. 45,000) to undergo a prospective
control for prostatic cancer. During 1999–2001, 1300
men were randomly assigned by postal code and
invited by letter to screen for AAA. One thousand and
forty-one (80%) agreed. Thirty-two men (3%) had
exclusion criteria (i.e. surgery during the last 6
months, liver disease, cancer or rheumatoid arthritis).
Twenty-two did not show up for ultrasound despite
repetitive invitation and were excluded. Finally, 987
men were enrolled in the study. All participants gave
written informed consent. The study was approved byEur J Vasc Endovasc Surg 29, 378–382 (2005)
doi:10.1016/j.ejvs.2004.12.007, available online at http://www.sciencedirect.com onved.
Table 1. Comparison of patients divided into age groups and
dilatation of the aorta at 25 shows normal distribution between
groups
Age AortaR25 mm
55–59 years (nZ332) nZ16 (4.8%)
60–64 years (nZ345) nZ25 (7.2%)
65–70 years (nZ310) nZ35 (11.3%)
All (nZ987) nZ76 (7.6%) PZ.0001
Expansion of aortic diameter with increasing age is significant
(PZ.0001).
Serum Markers in AAA 379the local ethical committee and the procedures were in
accordance with institutional guidelines.
The diameter of the infrarenal aorta was measured
by ultrasound (Panther 2002 Advanced Diagnostic
Imaging, B-K Medical, Germany) in an anterior–
posterior direction by three investigators. The largest
diameter was chosen. The first 20 examinations of each
investigator were cross-checked by an experienced
radiologist to control for accuracy. Twenty milliliter of
blood was obtained from the cubital vein of each
participant and stored atK25 8C. All participants were
screened with a standardized questionnaire for smok-
ing (current or past 5 years), hypertension, diabetes
mellitus and first-degree relatives with known aneur-
ysmal disease. Group 1 consisted of patients with
aortic dilatationR25 mm. A control group of 83 men
without aortic dilatation comprised Group 2. These
men were chosen at random (frequent given name)
from the remaining 911 men without aortic dilationO
25 mm. Group 3 (nZ19) consisted of patients with
known AAA that were operated on during study
recruitment.
Serum levels of MMP-2 and -9 and NIIINP were
determined in all three groups. MMP-2 and -9 were
batch-analyzed with use of a commercially available
enzyme-linked immunosorbent assay (ELISA) kit
specific for human MMP-2 and -9 (Amersham Bios-
ciences Europe GmbH, Freiburg, Germany). All
samples were analyzed in duplicate and averaged. If
the MMP sample levels from a patient varied byO
10%, the serum was retested in triplicate and the
averaged value was taken. The within-assay precision
(!6%) and the between-assay precision (!10%) were
determined by the manufacturer. PIIINP values were
determined with a standardized radioimmuno-assay
test (Orion Diagnostica, Espoo, Finland) in the same
fashion.
Data were analyzed by STATA (Stata Corporation,
College Station, TX, USA). All data are presented as
meanGSD. The Wilcoxon’s rank test was used to
compare two groups with measured values and the
Kruskal–Wallis test was used to compare more than
two groups. Rank correlation according to Spearman
was used to assess dependent variables. Statistical
significance was set at P!.05.ResultsFig. 1. Distribution of serum values of NIIINP in relation to
aortic diameter (mm). PZ.378 for comparison of all three
groups (Kruskal–Wallis test). Aorta, aortic diameter; s,
values of Group 1 (patients with aortic dilatationR25 mm,
nZ76); k, values of Group 2 (randomized population
without aortic dilatation, nZ83); g2, values of Group 3
(patients operated on for AAA, nZ19).Age and aortic diameter
Aortic dilatationR25 mm was present in 76 (7.7%) of
the 987 men. A diameter of 5 cm or more was found infive (0.5%) patients. The mean age of all men was 62.1
(G4.3) years. The mean age of men with aortic
dilatationR25 mm was 63.6 (G4.1) years. Age was
distributed normally within age groups (55–59, 60–64
and 65–70 years). Aortic diameter was correlated to
patients age (PZ0.0001, Table 1).Serum values and aortic diameter
Mean values for NIIINP were 322G130 mg/l (range
27–919), 312G101 mg/l (range 143–748) and 334G
113 mg/l (range 104–552) in Groups 1, 2 and 3,
respectively. Differences between groups were not
statistically significant (Table 2, Fig. 1). MMP-2 mean
values were 1473G287 (range 880–2320), 1468G343
(152–2640) and 1432G328 (980–2140) ng/ml in Groups
1, 2 and 3, respectively. There was no statistical
difference between the three groups (Table 2, Fig. 2).
For MMP-9 mean values were as follows: Group 1
371G284 (range 108–2044) ng/ml, Group 2 455G499
(102–4480) ng/ml and Group 3 281G125 (108–502)
ng/ml. These differences showed a weak statistical
significance between the three groups (PZ0.043,Eur J Vasc Endovasc Surg Vol 29, April 2005
Table 2. Comparison of values of NIIINP, MMP 2 and 9 between different groups of patients (SD standard deviation of the mean)
Group 1 (nZ76) Group 2 (nZ83) Group 3 (nZ19) P
NIIINP (mean, SD) 322 (G130) mg/l 312 (G101) mg/l 334 (G113) mg/l .378
MMP 2 (mean, SD) 1473 (G287) ng/ml 1468 (G342)ng/ml 1432 (G328) ng/ml .716
MMP 9 (mean, SD) 371 (G284) ng/ml 455 (G499) ng/ml 281 (G125) ng/ml .043
Group 1, patients with aortic dilatationR25 mm; Group 2, population without aortic dilatation; Group 3, patients operated on for AAA.
T. Eugster et al.380Table 2). Regression analysis was negative, i.e. MMP-9
values for aortas with higher diameter were lower
(Table 2, Fig. 3).Discussion
Different histopathologic studies have demonstrated
that aneurysmal tissue is characterized by elevation in
elastolytic and collagenolytic activity.16–22 Satta et al.
found elevated serum levels for NIIINP in patients
with AAA compared to patients with peripheral
arterial occlusive disease (PAOD).10 In a follow-up
study over 3 years the values for NIIINP increased
according to enlarging aortic diameter.14 In our study,
we found no correlation of higher serum levels of
NIIINP and a larger diameter of the infrarenal aorta. A
possible explanation for the disparity in the findings
may be that the control group in Satta’s study were
patients with PAOD. Our control group consisted of a
randomized population of 911 men of the same age as
the patients with aortic dilatation. In another study,
Lindholt and coworkers23 were not able to show a
correlation between dimension of AAA and NIIINP
blood levels. In a follow-up study with elastin and
collagen markers, NIIINP was not useful in predictingFig. 2. Distribution of serum values of MMP-2 in relation to
aortic diameter. PZ.716 for comparison of all three groups
(Kruskal–Wallis test). Aorta, aortic diameter; s, values of
Group 1 (patients with aortic dilatationR25 mm, nZ76); k,
values of Group 2 (randomized population without aortic
dilatation, nZ83); g2, values of Group 3 (patients operated
on for AAA, nZ19).
Eur J Vasc Endovasc Surg Vol 29, April 2005expansion of the AAA to a size requiring surgery.24 In
accordance with our results and the discussed studies
we conclude that NIIINP does not seem to be a serum
marker for AAA.
In 1991, Vine25 described the important role of
metalloproteinases in degenerative aortic disease. This
paper was followed by publications dealing with the
behavior of matrix metalloproteinases in the wall of
the infrarenal aorta and its influence on smooth
muscle cells.26–29 All these investigations were per-
formed with aneurysmatic aortic wall tissue. McMil-
lan et al.30 reported a relationship between the
diameter of the AAA and MMP-9 values. They
found the highest amount of MMP-9 in the wall of
aortic aneurysms with a diameter between 5 and
6.9 cm. They concluded that MMP-9 may be respon-
sible for the dilatation of the AAAs over 5 cm. As in
previous studies, this study included only a small
number of patients (nZ19).
Freestone et al.31 were able to show that MMP-2 was
the dominating enzyme in the wall of small early
aneurysms. Later, with increasing aortic diameter and
predominant inflammatory reaction in the aortic wall,
MMP-9 became the leading elastolytic enzyme. In a
follow-up study, McMillan and Pearce32 reported
elevated plasma levels of MMP-9 in patients withFig. 3. Distribution of serum values of MMP-9 in relation to
aortic diameter (mm). PZ.043 for comparison of all three
groups (Kruskal–Wallis test). The Y-axis scale is logarithmic.
Aorta, aortic diameter; s, values of Group 1 (patients with
aortic dilatationR25 mm, nZ76), k, values of Group 2
(randomized population without aortic dilatation, nZ83);
g2, values of Group 3 (patients operated on for AAA, nZ19).
Serum Markers in AAA 381AAA compared to patients with PAOD and to healthy
control patients. Patients with AAA, however, were
significant older (mean age 72.7 years) than patients
with PAOD (mean age 60.5 years) and members of the
healthy control group (mean age 35.3 years). An
influence of age can, therefore, not be excluded.
Hovsepian et al.15 described elevated plasma levels
for MMP-9 in patients with AAA. After surgical
correction of the AAA MMP-9 values returned to
normal. Several investigators described decreasing
levels of MMP-9 and possibly MMP-2 after operation
of an AAA.33,34 After endovascular aneurysm the
values seem to decrease faster than after open fixation
of an AAA.
Our results do not support these previous investi-
gations. In our study, we found no correlation between
serum levels of MMP-2 and -9 and the diameter of the
AAA. There are some shortcomings to our study. A
possible explanation for the disparate results is the
long duration of the recruitment procedure. In order to
achieve a higher study power, some 1000 men were
screened for aortic aneurysm. The advantage of this
action was to achieve an ideal representative popu-
lation for AAA. The disadvantage consisted of the
time needed (i.e. more than 2 years) to recruit and
screen all men included. Therefore, we believe that the
time-factor was not relevant.
A sound explanation for elevated MMP-9 levels is
suggested by Lindholt et al.23 They reported a large
difference between median serum and plasma values
for MMP-9, possibly due to release of these proteases
and their protease inhibitors upon platelet activation.
This finding still does not explain the lower values of
MMP-9 in patients with AAA compared to those of
patients with normal aortas.
In conclusion, we found no predictive value of
NIIINP, MMP-2 and -9 as serum markers for AAA.
Our results are in contradiction to previous studies.
Further studies with platelet-free plasma are still
necessary to prove the value of NIIINP, MMP-2 and
-9 as circulating markers for AAA.Acknowledgements
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